DAE HWA Pharmaceutical Co. Ltd (067080) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DAE HWA Pharmaceutical Co. Ltd stock KRW 1,273, price KRW 8,820, that is 85.6% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 5,630 KRW – 23,032 KRW · fair‑value band 878.91 KRW – 1,825 KRW · the 8,820 KRW price screens above the 1,273 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow DAE HWA Pharmaceutical Co. in your weekly email
Every Wednesday you see whether DAE HWA Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea.
Show moreShow less
The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products.
It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients.
The company also exports its products to approximately 22 countries, including Asia, South America, the Middle East, and Africa. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.
Stock analysis
DAE HWA Pharmaceutical Co. Ltd (067080) currently trades at 8,820 KRW, while our model-based Fair Value estimate is 1,273 KRW, 86% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 1,750 KRW per share, and 1 of the 21 models we run sit above the 8,820 KRW price.
Bear case: the Earnings-Based group reads lowest at 763.41 KRW, and 20 of the 21 models stay below the price. Data coverage for this calculation is low.
Scenario range: 878.91 KRW (bear) to 1,825 KRW (bull), the price of 8,820 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DAE HWA Pharmaceutical Co. Ltd reported revenue of 143B KRW in FY2025 versus 117B KRW in FY2021, a compound +5.1%/yr. Reported net income was 1.7B KRW in FY2025, compounding −7.1%/yr from FY2021.
Key figures
Market cap 163B KRW (≈ $121M) Micro · P/E ratio 36.2 · P/S ratio 1.55 · EPS (TTM) 240.68 KRW · Dividend yield 1.7% · Net margin 3.0% · Return on equity 6.1% · Return on assets (EBIT) 1.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 62% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −86%, 067080 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (373.65 KRW to 10,692 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear878.91 KRWFair Value 1,273 KRWBull1,825 KRW
Price 8,820 KRW · Downside -85.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (77.76 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +0.3% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +4.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.3%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−23.9% vs −7.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 101% above its own trend.
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
Compare DAE HWA Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−85.6% · Bottom 25%
Profitability
Return on equity (12 months)6.1% · Below median
Return on assets1.1% · Below median
Net margin (12 months)4.2% · Below median
Operating margin (12 months)8.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)14.8% · Above median
Dividend yield (12 months)1.7% · Above median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DAE HWA Pharmaceutical Co. Ltd (067080) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1,273 KRW versus a price of 8,820 KRW, about 86% lower (overvalued).
What is the fair value of 067080?
Our model-based fair value for DAE HWA Pharmaceutical Co. Ltd is 1,273 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 8,820 KRW.
What is the quality score of 067080?
DAE HWA Pharmaceutical Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DAE HWA Pharmaceutical Co. Ltd (067080)?
Our model-based price target is the fair value of 1,273 KRW (as of Nov 8, 2026) from 21 valuation models. Cautious scenario 878.91 KRW, optimistic scenario 1,825 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DAE HWA Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 1,273 KRW, about 86% lower versus a price of 8,820 KRW (overvalued). Cautious scenario 878.91 KRW, optimistic scenario 1,825 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DAE HWA Pharmaceutical Co. Ltd (067080)?
DAE HWA Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 149B KRW (latest available figure, as of Nov 8, 2026).
Does DAE HWA Pharmaceutical Co. Ltd pay a dividend?
DAE HWA Pharmaceutical Co. Ltd currently shows a dividend yield of 1.70% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of DAE HWA Pharmaceutical Co. Ltd (067080) and when is the ex-dividend date?
DAE HWA Pharmaceutical Co. Ltd pays a dividend of 150.00 KRW per share a year, a dividend yield of 1.7%. The last ex-dividend date was Jun 29, 2026. A dividend has been paid every year since at least 2003. The payout ratio is 62.3% of earnings. Free cash flow covers the dividend 0.25 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into DAE HWA Pharmaceutical Co. Ltd (067080)?
For today's price to be fair in a discounted-cash-flow model, DAE HWA Pharmaceutical Co. Ltd would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 067080 use?
Our models discount DAE HWA Pharmaceutical Co. Ltd at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DAE HWA Pharmaceutical Co. Ltd that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has DAE HWA Pharmaceutical Co. Ltd (067080) delivered so far?
Over the past 5 years revenue at DAE HWA Pharmaceutical Co. Ltd grew +5.5 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DAE HWA Pharmaceutical Co. Ltd (067080) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DAE HWA Pharmaceutical Co. Ltd (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DAE HWA Pharmaceutical Co. Ltd (067080)?
The free-cash-flow yield on the price is 0.45 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow DAE HWA Pharmaceutical Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DAE HWA Pharmaceutical Co. Ltd (067080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DAE HWA Pharmaceutical Co. Ltd it is 1,273 KRW per share (as of Nov 8, 2026), against a price of 8,820 KRW. It is the blended result of 21 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DAE HWA Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 067080 trades above its calculated fair value: price 8,820 KRW, fair value 1,273 KRW, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 067080?
No. The price is what the market pays today (8,820 KRW); the fair value is what the company's own numbers justify (1,273 KRW). For DAE HWA Pharmaceutical Co. Ltd the two are 7,547 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DAE HWA Pharmaceutical Co. Ltd worth?
The market values DAE HWA Pharmaceutical Co. Ltd at about 163B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 8,820 KRW; our models calculate a fair value of 1,273 KRW per share.
What do the bullish and bearish scenarios say about 067080?
Our models span a range for DAE HWA Pharmaceutical Co. Ltd: cautious scenario 878.91 KRW, base 1,273 KRW, optimistic 1,825 KRW per share (as of Nov 8, 2026, price 8,820 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 067080?
DAE HWA Pharmaceutical Co. Ltd trades at a price-to-earnings ratio of 36.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,273 KRW is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings: 92.1. Other multiples: P/B 2.2, P/S 1.5, EV/EBITDA 19.9.
How solid is the balance sheet of DAE HWA Pharmaceutical Co. Ltd (067080)?
Balance-sheet figures for DAE HWA Pharmaceutical Co. Ltd (as of Nov 8, 2026): return on equity 6.1%, debt of 0.05 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 067080 from its 52-week high?
DAE HWA Pharmaceutical Co. Ltd trades at 8,820 KRW, about 62% below its 52-week high of 23,032 KRW and 12% above the low of 7,870 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,273 KRW is for.
Which stocks are comparable to DAE HWA Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DAE HWA Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 8,820 KRW, calculated fair value 1,273 KRW (−86%), Quality Score 47/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 067080 calculated?
We run DAE HWA Pharmaceutical Co. Ltd through 21 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,273 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DAE HWA Pharmaceutical Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DAE HWA Pharmaceutical Co. Ltd (067080)?
The closing price on Nov 6, 2026 was 8,820 KRW. Our model-based fair value is 1,273 KRW, about 86% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DAE HWA Pharmaceutical Co. Ltd right now?
The price sits above even our optimistic bull case (1,825 KRW). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (878.91 KRW to 1,825 KRW) leaves room in how you read the outcome.
Key figures of DAE HWA Pharmaceutical Co. Ltd
How large is the market capitalisation of DAE HWA Pharmaceutical Co. Ltd (067080)?
The market capitalisation of DAE HWA Pharmaceutical Co. Ltd is 163B KRW (≈ $121M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DAE HWA Pharmaceutical Co. Ltd (067080)?
The price-to-sales ratio of DAE HWA Pharmaceutical Co. Ltd is 1.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DAE HWA Pharmaceutical Co. Ltd (067080)?
Earnings per share at DAE HWA Pharmaceutical Co. Ltd are 240.68 KRW (price ÷ EPS = P/E 36.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DAE HWA Pharmaceutical Co. Ltd (067080)?
The dividend yield of DAE HWA Pharmaceutical Co. Ltd is 1.7% (payout 62.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DAE HWA Pharmaceutical Co. Ltd (067080)?
The net margin of DAE HWA Pharmaceutical Co. Ltd is 3.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DAE HWA Pharmaceutical Co. Ltd (067080)?
The return on equity (ROE) of DAE HWA Pharmaceutical Co. Ltd is 6.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DAE HWA Pharmaceutical Co. Ltd (067080)?
On an EBIT basis the return on assets of DAE HWA Pharmaceutical Co. Ltd is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DAE HWA Pharmaceutical Co. Ltd (067080)?
The operating margin of DAE HWA Pharmaceutical Co. Ltd is 8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DAE HWA Pharmaceutical Co. Ltd (067080)?
Revenue at DAE HWA Pharmaceutical Co. Ltd is growing +14.8% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DAE HWA Pharmaceutical Co. Ltd (067080)?
Earnings per share at DAE HWA Pharmaceutical Co. Ltd are growing +112% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DAE HWA Pharmaceutical Co. Ltd (067080) carry?
The net debt of DAE HWA Pharmaceutical Co. Ltd is 95.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DAE HWA Pharmaceutical Co. Ltd in the live analysis
One click puts DAE HWA Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026